Does our current understanding of immune tolerance, autoimmunity, and immunosuppressive mechanisms facilitate the design of efficient cancer vaccines?

Scandinavian Journal of Immunology

Volumn 70, Issue 6, 2009, Pages 516-525

  Sioud, M ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DENDRITIC CELL VACCINE; IMIQUIMOD; MYELIN BASIC PROTEIN; MYELIN BASIC PROTEIN[85-99]; RNA; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

AUTOIMMUNITY; CELL FUNCTION; COMPREHENSION; DENDRITIC CELL; ENDOSOME; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; SKIN TUMOR; T LYMPHOCYTE; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, NEOPLASM; AUTOIMMUNITY; CANCER VACCINES; DENDRITIC CELLS; ENDOSOMES; HUMANS; IMMUNE TOLERANCE; IMMUNITY, INNATE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR MIMICRY; NEOPLASMS; T-LYMPHOCYTE SUBSETS; TOLL-LIKE RECEPTORS;

EID: 70450015746     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2009.02326.x     Document Type: Review

References (91)

1. Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science 2004 305 : 200 205.
2. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000 74 : 181 273.
3. Kang SM, Compans RW. Host responses from innate to adaptive immunity after vaccination: molecular and cellular events. Mol Cells 2009 27 : 5 14.
4. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunol 2002 3 : 991 998.
5. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that re mediated by tumor cells. Annu Rev Immunol 2007 25 : 267 296.
6. Hogquist KA, Baldwin TA, Jameson SC. Central tolerance: learning self-control in the thymus. Nat Rev Immunol 2005 5 : 772 782.
7. Arnold B, Schonrich G, Harmmerling GJ. Multiple levels of peripheral tolerance. Immunol Today 1993 14 : 12 4.
8. Melamed D, Nemazee D. Self-antigen does not accelerate immature B cell apoptosis, but stimulates receptor editing as a consequence of developmental arrest. Proc Natl Acad Sci USA 1997 94 : 9267 9272.
9. McGargill MA, Derbinski J, Hogquist K. Receptor editing in developing T cells. Nat Immunol 2000 1 : 336 341.
10. Kretz-Rommel A, Rubin RL. Disruption of positive selection of lymphocytes causes autoimmunity. Nat Med 2000 6 : 298 305.
11. Walker L, Abbas AK. The enemy within: keeping self-reactive T cells at bay in the periphery. Nature Rev Immunol 2001 21 : 11 9.
12. Leslie D, Lipsky P, Notkins AL. Autoantibodies as predictors of disease. J Clin Invest 2001 108 : 1417 1422.
13. Malo KJ, Powrie F. Regulatory T cells in the control of immune pathology. Nat Immunol 2001 2 : 816 822. (Pubitemid 34906442)
14. Mottet C, Uhlig HH, Powrie F. Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells. J Immunol 2003 170 : 3939 3943.
15. Tran DQ, Shevach EM. Therapeutic potential of FOXP3+ regulatory T cells and their interaction with dendritic cells. Human Immunol 2009 70 : 294 299.
16. Bennett CL, Christie J, Ramsdell F et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001 27 : 20 1.
17. Sharma MD, Hou DY, Liu Y et al. Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph node. Blood 2009 113 : 6102 6111.
18. Baban B, Chandler PR, Sharma MD et al. IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J Immunol 2009 183 : 2475 2483.
19. Gregersen PK, Olsson LM. Recent advances in the genetics of autoimmune disease. Annu Rev Immunol 2009 27 : 363 391.
20. Mocci S, Lafferty K, Howard M. The role of autoantigen in autoimmune disease. Curr Opin Immunol 2000 12 : 725 730.
21. Marrack P, Scott-Browne JP, Dai S, Gapin L, Kappler JW. Evolutionarily conserved amino acids that control TCR-MHC interaction. Annu Rev Immunol 2008 26 : 171 203.
22. McDevitt HO. The role of MHC class II molecules in susceptibility and resistance to autoimmunity. Curr Opin Immunol 1998 10 : 677 681.
23. Davis JM. Molecular mimicry: can epitope mimicry induce autoimmune disease? Immunol Cell Biol 1997 75 : 113 126.
24. Fujinami RS. Can virus infections trigger autoimmune disease? J Autoimmun 2001 16 : 229 234.
25. Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995 80 : 695 705.
26. Christen U, Edelmann KH, McGavern DB et al. A viral epitope that mimics a self antigen can accelerate but not initiate autoimmune diabetes. J Clin Investig 2004 114 : 290 1298.
27. Srinivasappa J, Saegusa J, Prabhakar BS et al. Molecular mimicry: frequency of reactivity of monoclonal antiviral antibdies with normal tissues. J Virol 1986 57 : 397 401.
28. Quale AJ, Wilson KB, Li SG et al. Peptide recognition, T cell receptor usage and HLA restriction elements of human heat-shock protein (hsp) 60 and mycobacterial 65-kDa hsp-reactive T cell clones from rheumatoid synovial fluid. Eur J Immunol 1992 22 : 1315 1322.
29. Greene MT, Ercolini AM, Degutes M, Miller SD. Differential induction of experimental autoimmune encephalomyelitis by myelin basic protein molecular mimics in mice humanized for HLA-DR2 and an MDP(85-99)-specific T cell receptor. J Autoimmun 2008 31 : 399 407.
30. Williams RO, Feldmann M, Maini RN. Anti-tumour necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992 89 : 9784 9788.
31. Lang KS, Recher M, Junt T et al. Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat Med 2005 11 : 138 145.
32. Gordon TP. Determinant spreading: lessons from animal models and human disease. Immunol Rev 1998 164 : 209 229.
33. Lehmann PV, Forsthuber T, Miller A, Sercarz EE. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 1992 359 : 155 157.
34. Butterfield LH, Ribas A, Dissette VB et al. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 2003 9 : 998 1008.
35. Hansen MH, Østenstad B, Sioud M. Antigen-specific IgG antibodies in stage IV long-term survival breast cancer patients. Mol Med 2001 7 : 230 239.
36. Hansen MH, Østenstad B, Sioud M. Identification of immunogenic antigens using a phage-displayed cDNA library from an invasive ductal breast carcinoma tumour. Int J Oncol 2001 19 : 1303 1309.
37. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005 23 : 1147 1157.
38. Houghton AN. Cancer antigens: immune recognition of self and altered self. J Exp Med 1994 180 : 1 4.
39. Sioud M, Hansen MH. Profiling the immune response in patients with breast cancer by phage-displayed cDNA libraries. Eur J Immunol 2001 31 : 716 725.
40. Sioud M. How does autoimmunity cause tumor regression? A potential mechanism involving cross-reaction through epitope mimicry. Mol Med 2002 8 : 115 119.
41. Valmori D, Fonteneau JF, Lizana CM et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol 1998 160 : 1750 1758.
42. Bae J, Martinson JA, Klingemann HG. Heteroclitic CD33 peptide with enhanced anti-acute myeloid leukemic immunogenicity. Clin Cancer Res 2004 10 : 7043 7052.
43. Zhao L, Liu Z, Fan D. Overview of mimotopes and related strategies in tumor vaccine development. Expert Rev Vaccines 2008 7 : 1547 1555.
44. Linnemann T, Tumenjargal S, Gellrich S et al. Mimotopes for tumor-specific T lymphocytes in human cancer determined with combinatorial peptide libraries. Eur J Immunol 2001 31 : 156 165.
45. Toudot S, Scardino A, Sllaloustrou W et al. A general strategy to enhance immunogenicity of low-affinity HLA-A2.1-associated peptides: implication in the identification of cryptic tumor epitopes. Eur J Immunol 2000 30 : 3411 3421.
46. Sioud M, Sørensen D. Generation of an effective anti-tumor immunity after immunization with xenogeneic antigens. Eur J Immunol 2003 33 : 38 45.
47. Iversen PO, Emanuel PD, Sioud M. Targeting Raf-1 gene expression by a DNA enzyme inhibits juvenile myelomonocytic leukemia cell growth. Blood 2002 99 : 4147 4153.
48. Iversen PO, Sioud M. Modulation of granulocyte-macrophage colony-stimulating factor gene expression by a tumor necrosis factor specific ribozyme in juvenile myelomonocytic leukemic cells. Blood 1998 92 : 4263 4268.
49. Kolb HJ, Schattenberg A, Goldman JM et al. European Group for blood and marrow transplantation working party chronic leukemia. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995 86 : 2041 2050.
50. Stauss HJ. Immunotherapy with CTLs restricted by nonself MHC. Immunol Today 1999 20 : 180 183.
51. Gao L, Yang TH, Tourdot S, Sadovnikova E, Hasserjian R, Stauss HJ. Allo-major histocompatibility complex-restricted cytotoxic T lymphocytes engraft in bone marrow transplant recipients without causing graft-versus-host disease. Blood 1999 94 : 2999 3006.
52. Amrolia PJ, Reid SD, Gao L et al. Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity. Blood 2003 101 : 1007 1014.
53. Bae J, Martinson JA, Klingemann HG. Identification of CD19 and CD20 peptides for induction of antigen-specific CTLs against B-cell malignancies. Clin Cancer Res 2005 11 : 1629 1638.
54. Moris A, Teichgraber V, Gauthier L, Buhring HJ, Rammensee HG. Cutting edge: characterization of allorestricted and peptide-selective alloreactive T cells using HLA-tetramer selection. J Immunol 2001 166 : 4818 4821.
55. Bae J, Martinson JA, Klingemann HG. Identification of novel CD33 antigen-specific peptides for the generation of cytotoxic T lymphocytes against acute myeloid leukemia. Cell Immunol 2004 227 : 38 50.
56. Marijt WA, Heemskerk MH, Kloosterboer FM et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci USA 2003 100 : 2742 2747.
57. Heemskerk MH, Hoogeboom M, de Paus RA et al. Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. Blood 2003 102 : 3530 3540.
58. Dembic Z, Haas W, Weiss S et al. Transfer of specificity by murine alpha and beta T cell receptor genes. Nature 1986 320 : 232 238.
59. Clay TM, Custer MC, Sachs J, Hwu P, Rosenberg SA, Nishimura MI. Efficient transfer of a tumor antigen-reactive TcR to humn peripheral blood lymphocytes confers anti-tumour reactivity. J Immunol 1999 163 : 507 513.
60. Stanislawski T, Voss RH, Lotz C et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol 2001 2 : 962 970.
61. McMahan C, Fink P. Receptor revision in peripheral T cells creates a diverse v beta repertoire. J Immunol 2000 165 : 6902 6907.
62. Janicki CN, Jenkinson SR, Williams NA, Morgan DJ. Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration. Cancer Res 2008 68 : 2993 3000.
63. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003 21 : 335 376.
64. Trombetta ES, Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol 2005 23 : 975 1028.
65. Shi GP, Bryant RA, Riese R et al. Role for cathepsin F in invariant chain processing and major histocompatibility complex class II peptide loading by macrophages. J Exp Med 2000 191 : 1177 1186.
66. Sadegh-Nasseri S, Chen M, Narayan K, Bouvier M. The convergent roles of tapasin and HLA-DM in antigen presentation. Trends Immunol 2008 29 : 141 147.
67. Blander JM, Medzhitov R. Regulation of phagosome maturation by signals from toll-like receptors. Science 2004 304 : 1014 1018.
68. Cekaite L, Furset G, Hovig E, Sioud M. Gene expression analysis in blood cells in response to unmodified and 2′-modified siRNAs reveals TLR-dependent and independent effects. J Mol Biol 2007 365 : 90 108.
69. Spaner D. Amplifying cancer vaccine responses by modifying pathogenic gene programs in tumour cells. J Leukoc Biol 2004 76 : 338 351.
70. Spaner DE, Masellis A. Toll-like receptor agonists in te treatment of chronic lymphocytic leukeminia. Leukemia 2007 21 : 53 60.
71. Furset G, Sioud M. Design of bifunctional siRNAs: combining immunostimulation and gene-silencing in one single siRNA molecule. Biochem Biophys Res Commun 2007 352 : 642 649.
72. Moudgil KD, Sercarz EE. The T cell repertoire against cryptic self determinants and its involvement in autoimmunity and cancer. Clin Immunol Immunopathol 1994 73 : 283 289.
73. Banchereau J, Briere F, Caux C et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000 18 : 767 811.
74. Bonasio R, Scimone ML, Schaerli P, Grabie N, Lichtman AH, von Andrian Ulrich H. Clonal deletion of thymocytes by circulating dendritic cells homing to the thymus. Nat Immunol 2006 10 : 1092 1100.
75. Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR. Interleukin 10. Annu Rev Immunol 1993 11 : 165 190.
76. Lee GK, Park HJ, Macleod M, Chandler P, Munn DH, Mellor AL. Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division. Immunology 2002 107 : 452 460.
77. Munn DH, Mellor AL. IDO and tolerance to tumors. Trends Mol Med 2004 10 : 15 8.
78. Munn DH, Zhou M, Attwood JT et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998 281 : 1191 1193.
79. Mellor AL, Munn DH. Tryptophan catabolism prevents maternal T cells from activating lethal anti-fetal immune responses. J Reprod Immunol 2001 52 : 5 13.
80. Munn DH, Sharma MD, Hou D et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 2004 114 : 280 290.
81. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001 411 : 494 498.
82. Sioud M. Therapeutic siRNAs. Trends Pharmacol Sci 2004 25 : 22 8.
83. Flatekval FG, Sioud M. Modulation of DC maturation and function by mono- and bifunctional small interfering RNAs targeting indoleamine 2,3 dioxygenase. DOI
84. Yoneyama M, Kikuchi M, Natsukawa T et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004 5 : 730 737.
85. Poeck H, Besch R, Maihoefer C et al. 5′-triphosphate-siRNA: turning gene silencing and RIG-1 activation against melanoma. Nature Med 2008 14 : 1256 1263.
86. Beutelspacher SC, Pillai R, Watson MP et al. Function of indoleamine 2,3-dioxygenase in corneal allograft rejection and prolongation of allograft survival by over-expression. Eur J Immunol 2006 36 : 690 700.
87. Jasperson LK, Bucher C, Panoskaltsis-Mortari A et al. Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality. Blood 2008 111 : 3257 3265.
88. Steckel NK, Kuhn U, Beelen DW, Elmaagacli AH. Indoleamine 2,3-dioxygenase expression in patients with acute graft-versus-host disease after allogeneic stem cell transplantation and in pregnant women: association with the induction of allogeneic immune tolerance? Scand J Immunol 2003 57 : 185 191.
89. Larsen L, Ropke C. Suppressors of cytokine signalling: SOCS. APMIS 2002 110 : 833 844.
90. Shen L, Evel-Kabler K, Strube R, Chen SY. Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumour imunity. Nat Biotechnol 2004 22 : 1546 1553.
91. Bocchia M, Gentili S, Abruzzese E et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 2005 365 : 657 662.